Related Experiment Videos
Treatment of systemic sclerosis
1Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract:
A new awareness of the challenges and pitfalls of clinical research in patients with systemic sclerosis has recently arisen. Several editorials discussed concern about the design of therapeutic trials and the need to use established scientific standards to find better markers of disease activity and better ways to measure improvement or deterioration of organ involvement, including the heart, lung, and gastrointestinal tract. This year, an uncontrolled experience in the use of D-penicillamine in the treatment of patients with rapidly progressive skin involvement was reported. In addition, a multicenter study of photopheresis demonstrated benefit compared with D-penicillamine. Several new prokinetic drugs demonstrated promise for the treatment of gastrointestinal disease in patients with systemic sclerosis. Although studies continue to demonstrate the benefit of intravenous prostaglandins in the treatment of Raynaud's phenomenon and digital ulcers in scleroderma, an initial report of oral prostaglandins was disappointing. Clinical researchers are now working together to design multicenter studies and to define new uniform standards of disease activity so that the appropriate treatment for systemic sclerosis can be determined.
Insights
Clinical research for systemic sclerosis faces challenges. New standards and multicenter studies are needed to determine effective treatments for this complex autoimmune disease.
Area of Science:
- Rheumatology
- Clinical Research Methodology
- Systemic Sclerosis Research
Background:
- Growing concerns regarding the design and standards of clinical trials for systemic sclerosis.
- Need for improved disease activity markers and outcome measures for organ involvement (heart, lung, GI tract).
Purpose of the Study:
- To address challenges in systemic sclerosis clinical research.
- To highlight recent therapeutic trial findings and the need for standardized research approaches.
Main Methods:
- Review of recent clinical research experiences and published studies.
- Discussion of therapeutic agents like D-penicillamine, photopheresis, prokinetic drugs, and prostaglandins.
- Emphasis on the development of multicenter studies and uniform disease activity standards.
Main Results:
- Photopheresis showed benefit over D-penicillamine in a multicenter study.
- New prokinetic drugs show promise for gastrointestinal manifestations.
- Intravenous prostaglandins remain beneficial for Raynaud's phenomenon and digital ulcers, but oral prostaglandins were disappointing.
Conclusions:
- Clinical researchers are collaborating to design new multicenter studies.
- Establishing uniform standards for disease activity is crucial for determining appropriate treatments for systemic sclerosis.